Daewoong Pharmaceutical announced on October 31 that it has signed a joint sales agreement with Celltrion Pharm to market CT-P41 ...

The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.

The EMA has accepted a MAA for Alvotech and Advanz Pharma’s AVT05, a proposed biosimilar to Johnson & Johnson’s (J&J) Simponi ...

Alvotech (ALVO) has released an update. Alvotech, in collaboration with Advanz Pharma, has announced the acceptance of its Marketing ...

Alvotech (ALVO) and Advanz Pharma announced that the European Medicines Agency has accepted a Marketing Authorization Application for AVT05, ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

The FDA’s anticipated decision and EMA’s expected opinion are anticipated in the second half of 2025. Baca Juga Teva Statement on European Commission Decision; Company to Appeal TVB-009P, Teva’s ...

Biogen BIIB reported third-quarter 2024 adjusted earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate ...

Organon (NYSE:OGN) and partner Shanghai Henlius Biotech said the FDA has accepted the Biologics License Application for HLX14 ...

The withdrawal follows discussions with the EMA’s Committee for Medicinal Products for Human Use (CHMP). AMD is a significant cause of central vision loss in the elderly, often affecting both eyes.